A Phase I Study T Cell Receptor-Redirected T Cells Infusions in Subjects With Recurrent HBV-Related Hepatocellular Carcinoma in Post Liver Transplantation
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2018
Price : $35 *
At a glance
- Drugs HBV specific TCR redirected T-cell therapy-Lion TCR (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Lion TCR
- 16 Sep 2018 Planned End Date changed from 1 Nov 2020 to 1 Dec 2019.
- 16 Sep 2018 Planned primary completion date changed from 1 Nov 2017 to 1 May 2019.
- 01 Jun 2018 New trial record